• 1
    Gold BD, Colletti RB, Abbott M, et al. North American Society for Pediatric Gastroenterology and Nutrition. Helicobacter pylori infection in children: recommendations for diagnosis and treatment. J Pediatr Gastroenterol Nutr 2000; 31: 4907.
  • 2
    Oderda G, Marinello D, Lerro P, et al. Dual vs. triple therapy for childhood Helicobacter pylori gastritis: a double-blind randomized multicentre trial. Helicobacter 2004; 9: 293301.
  • 3
    Deltenre M, Ntounda R, Jonas C, et al. Eradication of Helicobacter pylori: Why does it fail? Ital J Gastroenterol Hepatol 1998; 30 (Suppl. 3): 3268.
  • 4
    Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 137484.
  • 5
    Adamsson I, Nord CE, Lundquist P, Sjostedt S, Edlund C. Comparative effects of omeprazole, amoxycillin, plus metronidazole vs. omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother 1999; 44: 62940.
  • 6
    Nista EC, Candelli M, Cremonini F, et al. Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther 2004; 20: 11818.
  • 7
    Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 27449.
    Direct Link:
  • 8
    Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 2006; 23: 107786.
  • 9
    Hamilton-Miller JM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 2003; 22: 3606.
  • 10
    Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection—the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 16780.
  • 11
    Mitsuoka T. The human gastrointestinal tract. In: WoodBJB, ed. The Lactic Acid Bacteria, Essex, England: Elsevier Science Publ. Ltd, 1992: 69114.
  • 12
    Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Curr Issues Intest Microbiol 2001; 2: 4353.
  • 13
    Casas IA, Dobrogosz WJ. Validation of probiotic concept: L. reuteri confers broad-spectrum protection against disease in humans and animals. Microb Ecol Health Dis 2000; 12: 24785.
  • 14
    Valeur N, Engel P, Carbajal N, et al. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl Environ Microbiol 2004; 70: 117681.
  • 15
    Rowland M, Lambert I, Gormally S, et al. Carbon 13-labeled urea breath test for the diagnosis of Helicobacter pylori infection in children. J Pediatr 1997; 131: 81520.
  • 16
    Rutigliano V, Ierardi E, Francavilla R, et al. Helicobacter pylori and nonulcer dyspepsia in childhood: clinical pattern, diagnostic techniques, and bacterial strains. J Pediatr Gastroenterol Nutr 1999; 28: 296300.
  • 17
    Svedlund J, Sjodin I, Dotevall G. GSRS: a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 12934.
  • 18
    Zeiter DK, Hyams JS. Recurrent abdominal pain in children. Pediatr Clin North Am 2002; 49: 5371.
  • 19
    Francavilla R, Lionetti E, Castellaneta SP, et al. Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 2005; 129: 14149.
  • 20
    Peters DH, Clissold SP. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44: 11724.
  • 21
    Lewis SJ, Freedman AR. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998; 12: 80722.
  • 22
    D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002; 324: 13613.
  • 23
    Cremonini F, Di Caro S, Nista EC et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16: 14617.
  • 24
    Arvola T, Laiho K, Torkkeli S, et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999; 104: e64.
  • 25
    De Vrese M, Schrezenmeir J. Probiotics and non-intestinal infectious conditions. Br J Nutr 2002; 88 (Suppl. 1): 5966.
  • 26
    Tubelius P, Stan V, Zachrisson A. Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study. Environ Health 2005; 4: 2529 Global access available at
  • 27
    Shornikova AV, Casas IA, Mykkanen H, et al. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr Infect Dis J 1997; 16: 11037.
  • 28
    Wolf BW, Garleb K, Ataya D, et al. Safety and tolerance of Lactobacillus reuteri in healthy adults male subjects. Microb Ecol Health Dis 1995; 8: 4150.
  • 29
    Wolf BW, Wheeler KB, Ataya DG, et al. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food Chem Toxicol 1998; 36: 108594.
  • 30
    Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005; 115: 59.
  • 31
    Shornikova AV, Casas IA, Isolauri E, et al. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr 1997; 24: 399404.
  • 32
    Conway PL, Gorbach SL, Goldin BR. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci 1987; 70: 112.
  • 33
    Myllyluoma E, Veijola L, Ahlroos T, et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy–a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 2005; 21: 126372.
  • 34
    Mukai T, Asasaka T, Sato E, et al. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol 2002; 32: 10510.
  • 35
    Felley C, Michetti P. Probiotics and Helicobacter pylori. Best Pract Res Clin Gastroenterol 2003; 17: 78591.
  • 36
    Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999; 60: 2039.
  • 37
    Coconnier MH, Lievin V, Hemery E, et al. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol 1998; 64: 457380.